CACrown ArchivesThe cinema collection
EN/FR
Search
Menu
Research dossier · Science & Nature

Fispemifene

chemical compound

Specimen drawers, botanical folios and brass scientific instruments under study light
Science and natureInterpretive dossier study · Crown Archives visual atlas
Record originEnglish Wikipedia
Text licenseCC BY-SA 4.0
Source revisionDec 23, 2025
Entity authorityQ27258105 ↗
Source-derived summary

Fispemifene (INN, USAN) (developmental code name HM-101) is a nonsteroidal selective estrogen receptor modulator (SERM) of the triphenylethylene group that was developed for the treatment of male hypogonadism but was abandoned and never marketed. It reached phase II clinical trials for this indication before development was terminated in March 2016. The drug failed to achieve statistical significance on key effectiveness endpoints in clinical trials and was discontinued by its developer for strategic reasons.

Editorial summary

“Fispemifene” enters the record as chemical compound. Crown Archives preserves that source wording while asking what Fispemifene, chemical and compound can confirm, complicate or overturn.

Editorial reviewUseful for establishing the present vocabulary of the subject while preserving a route back to the evidence on which that vocabulary rests. The current lead gives the account dated anchors—2016—that can be checked directly. The selected authority fields contribute no independent date. Its strongest next move is a source search built around Fispemifene, chemical and compound.
Editorial analysis

Why this record matters

“Fispemifene” is worth following because a concise public description often conceals a longer documentary argument. Here, Fispemifene, chemical and compound provides the most credible route into that argument.

Evidence profile

Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Dec 23, 2025. The linked authority identifier is Q27258105. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2016.

Critical limits

A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.

How to read it

Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.

Best used for
  • Current terminology
  • Classification context
  • Finding cited technical literature
Verify next

Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.

Three-step research path

  1. Establish the record: confirm the title “Fispemifene”, its source revision and the description used here.
  2. Expand the search: follow Fispemifene primary sources, Fispemifene archive and Fispemifene research across catalogues and specialist indexes.
  3. Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.

Questions for further research

  1. Which source most directly establishes the central claim about “Fispemifene”?
  2. Is the terminology current, historical or disputed?
  3. Has classification or technical consensus changed since the cited source?
Subject index

Search terms from this dossier

Source & attribution

This entry incorporates text from “Fispemifene” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.